Matrix Plastic Products (Matrix), a custom manufacturer specializing in medical device injection molding, cleanroom plastic molding, and precision tooling, is expanding operations into a new 88,000-square-foot facility in Bloomingdale, Illinois. The move is designed to increase capacity for regulated medical programs—including higher-cavitation tools, tighter tolerance components, and ISO-classified cleanroom production—while adding dedicated space for early-stage engineering and New Product Introduction (NPI) support.
Matrix will share additional details about the expansion and service roadmap at MD&M West 2026 (3–5 February, Anaheim, California). Visit Booth 2287 to discuss cleanroom molding, precision tooling, and technical support for scaling medical plastic components.
TL;DR: Matrix is expanding in Bloomingdale, IL to grow medical device injection molding capacity, ISO 8 cleanroom output, and NPI engineering support—details available at MD&M West 2026.
Medical Device Injection Molding and Cleanroom Manufacturing in Bloomingdale, Illinois
The new Bloomingdale, IL facility is planned to support medical device OEMs and contract manufacturers with a production footprint optimized for regulated manufacturing workflows—from prototype builds to validated commercial production. The layout is intended to reduce material travel and changeover time through dedicated production cells, clearer segregation of controlled areas, and improved flow from tooling to molding to inspection.
Timeline clarity: Initial operational readiness is targeted for Q2 2026 (suitable for early engineering builds, process development, and validation planning), followed by a phased ramp toward broader commercial output by end of 2026 (aligned with customer qualification schedules and production transfer timing).
Regulatory and quality systems alignment: For medical programs, customers commonly expect structured quality systems such as ISO 13485 (medical devices—quality management systems) and alignment to FDA QSR (Quality System Regulation; in transition as FDA harmonizes with ISO 13485 concepts). Matrix’s expansion messaging reinforces the ability to support validated manufacturing approaches and electronic traceability expectations typical for regulated supply chains. For reference, see the ISO 13485 overview (ISO) and FDA’s Quality System (QS) Regulation page.
TL;DR: The Bloomingdale expansion is timed to support Q2 2026 engineering/validation activities and end-of-2026 scaled production, with quality-system expectations aligned to ISO 13485 and FDA QSR norms for medical device manufacturing.
Key Features of the New Matrix Facility (Capacity, Cleanroom, NPI, and Metrology)
The 88,000-square-foot buildout is structured around measurable manufacturing needs for medical device programs: throughput, repeatability, validation readiness, and inspection capability for tight-tolerance molded components.
- Space: 88,000 sq ft total footprint to enable additional production cells, staging, and controlled segregation between processes.
- Cleanroom: 3,300 sq ft of ISO 8 cleanroom space for ISO 8 cleanroom injection molding for medical devices and clean assembly/packaging workflows.
- NPI lab: Dedicated engineering space for NPI support for medical plastic components—DFM, prototype molding, material evaluation, and process development.
- Tooling + QA upgrades: Investment in tooling capability, automated handling, and upgraded inspection/metrology to support tighter tolerances and higher cavitation.
TL;DR: The expansion focuses on practical levers OEMs care about—more controlled cleanroom space, more scalable manufacturing cells, stronger NPI support, and better tooling/QA infrastructure.
Expanded ISO 8 Cleanroom Injection Molding for Medical Devices
The new plant includes 3,300 square feet of ISO 8 cleanroom space. ISO 8 refers to an ISO cleanroom classification (per ISO 14644) that limits airborne particulate concentration to defined thresholds—commonly used for molded medical components requiring contamination control during molding and assembly. See ISO 14644-1 (ISO) for cleanroom classification background.
Typical cleanroom-molded medical applications (examples) include:
- Diagnostic housings and fluidic subcomponents (often in the ~5–100 mm feature range)
- Drug-delivery device parts (e.g., actuator components, protective caps, and mechanisms)
- Surgical and procedural device components where particulate control is specified
Concrete manufacturing examples OEMs ask about: ISO 8 programs often include engineered resins such as medical-grade polypropylene (PP), polyethylene (PE), polycarbonate (PC), and thermoplastic elastomers (TPEs). Many cleanroom components fall in the 0.2 g to 50 g part-weight range and may require repeatable cosmetic and functional surfaces, with dimensional tolerances routinely in the ±0.001–0.003 in (±0.025–0.075 mm) range depending on geometry and material.
TL;DR: The 3,300 sq ft ISO 8 cleanroom supports controlled molding and assembly for medical parts—especially where particulate limits, validated processes, and repeatable cosmetics/dimensions matter.
NPI (New Product Introduction) Engineering Lab: DFM, Simulation, DOE, and Validation Readiness
A dedicated engineering lab will support NPI (New Product Introduction) workstreams—helping medical device OEMs and contract manufacturers move from concept to validated production with fewer surprises.
What the NPI lab is designed to support (typical gated flow):
- DFM (Design for Manufacturability) reviews: gating on draft, shutoffs, wall transitions, gating/venting concepts, and tolerance stack-up
- Moldflow analysis: simulation to predict fill/pack, weld lines, air traps, and potential warpage drivers (often used to reduce iteration cycles before steel)
- DOE (Design of Experiments): structured process windows for key parameters (melt temperature, pack/hold, cooling, clamp force) to improve robustness
- Design reviews & checkpoints: formal reviews at tool design freeze, first article, and pre-validation build readiness
- IQ/OQ/PQ planning: IQ (Installation Qualification), OQ (Operational Qualification), and PQ (Performance Qualification) planning to align documentation, sampling, and acceptance criteria before scale-up
This approach is intended to help customers reduce rework and compress schedules—especially on complex parts such as thin-wall housings, multi-feature snap fits, or components with functional sealing surfaces where process capability and repeatability drive long-term yield.
TL;DR: The NPI lab is built around an engineering-first, gated process—DFM + Moldflow + DOE + IQ/OQ/PQ planning—so programs transition to validation and scale with fewer tool/process iterations.
Tooling, Press Capacity, Automation, and Metrology: More Concrete Capability Signals
The expansion includes investment in molding presses, automation, tooling technologies, and quality assurance systems to better support high-volume and high-complexity medical molding. While specific asset lists may vary by program timing, medical OEMs typically evaluate a supplier’s ability to run:
- Press tonnage ranges appropriate for medical components (commonly 55–350 tons for many precision medical parts, with higher tonnage used as part size increases)
- High-cavitation tools (e.g., 8–64 cavities depending on part size, resin, and runner strategy) to reduce piece price and improve output
- Automation (robotic part handling, vision checks, and in-line packaging) to reduce handling variation and support traceability
- Metrology and inspection using tools such as CMM (Coordinate Measuring Machine) for dimensional verification, optical measurement for small features, and documented sampling plans tied to validation requirements
Electronic traceability systems are also increasingly standard for regulated programs—supporting lot genealogy, material traceability, and inspection record retention. For OEMs with strong compliance needs, this directly supports investigations, containment, and change control when revisions occur.
Data-driven differentiation (planned impact): Tripling available floor space enables Matrix to add parallel production cells and inspection capacity. For many medical molding operations, this type of expansion can translate into meaningful improvements such as shorter internal queue time for new tool launch activities and more concurrent validations—particularly during peak transfer periods in late 2026.
TL;DR: The expansion signals readiness for common medical OEM requirements—right-sized press capacity, higher cavitation opportunities, automation, and metrology (e.g., CMM)—plus electronic traceability to support regulated programs.
Risk Mitigation During Transition: Supply Continuity and Qualification Management
Medical device OEMs and contract manufacturers typically prioritize continuity of supply during facility moves and expansions. Matrix’s phased ramp (Q2 2026 operational readiness through end-of-2026 scale-up) is structured to support controlled transitions rather than “big-bang” cutovers.
How transition risk is commonly mitigated for regulated molded components:
- Phased transfers: move by product family or process cell to avoid simultaneous disruption
- Bridging builds: build safety stock ahead of equipment relocation where appropriate
- Validation strategy alignment: map what changes trigger revalidation (facility change, press change, tool move, resin/packaging change) and define protocols early
- Dual-sourcing options: evaluate parallel capacity and contingency planning for critical SKUs
- Documented change control: controlled updates to PFMEA (Process Failure Mode and Effects Analysis), control plans, and work instructions
For background on validation expectations and lifecycle thinking, OEM teams often reference FDA process validation guidance such as Process Validation: General Principles and Practices (FDA).
TL;DR: The move is planned as a phased ramp with practical continuity tools—phased transfers, bridging builds, and disciplined validation/change control—to reduce supply risk for regulated programs.
Application Examples (Anonymized): Why Added Space + NPI + Cleanroom Helps
Example 1: Scaling a diagnostic consumable without changing form/fit/function. A diagnostic OEM needed to scale a small molded consumable from pilot volumes to sustained production while maintaining tight dimensional control on fluid-path features. By applying early DFM and Moldflow review and then executing a DOE-defined process window, the program was able to move toward higher-cavitation tooling and increased output without introducing unplanned design changes that would have triggered downstream requalification.
Example 2: Transitioning a cleanroom-molded drug-delivery component with minimized downtime. A medical device contract manufacturer required a controlled transfer plan for a cleanroom-molded component used in a drug-delivery assembly. A staged approach (inventory bridging + validation plan alignment + incremental production cell commissioning) reduced cutover risk and provided a documented path to re-establish process capability after relocation.
TL;DR: The added cleanroom space and NPI/validation structure are most valuable when customers need to scale output, increase cavitation, or transfer regulated parts with controlled qualification and minimal disruption.
How to Prepare for Transfers to the New Facility (Action Steps for OEMs)
For OEM engineering, quality, and sourcing teams planning a 2026 transfer or new launch, the most effective starts are structured and early.
- Start with a technical data pack: drawings with critical-to-quality (CTQ) features, tolerance rationales, and resin/sterilization compatibility requirements
- Define the validation approach early: agree on IQ/OQ/PQ scope, sampling plans, and acceptance criteria before the first engineering build
- Plan for PPAP-like elements where required: although PPAP is automotive-rooted, many OEMs request similar evidence packages (capability, MSA, control plans) for medical plastics
- Schedule a DFM + tool review window: align on gate location, venting strategy, steel-safe decisions, and expected cavitation roadmap
- Discuss continuity strategy: identify which SKUs need bridging builds, safety stock, or dual-sourcing considerations during the 2026 ramp
TL;DR: OEMs can de-risk transfers by aligning early on CTQs, validation scope (IQ/OQ/PQ), DFM/tooling decisions, and continuity plans tied to the Q2–end-of-2026 ramp timeline.
Meet Matrix Plastic Products at MD&M West 2026 (and Next Steps)
Matrix Plastic Products will be at MD&M West 2026 (3–5 February, Anaheim) at Booth 2287 to discuss cleanroom molding, precision tooling, NPI support for medical plastic components, and the Bloomingdale facility transition plan.
Recommended next steps for engineering and sourcing teams: request a DFM consultation, schedule a technical transfer review, or submit an RFQ with your print package and annualized volume forecast so timelines can be mapped to Q2 2026 validation readiness and end-of-2026 scale-up.
TL;DR: Connect at MD&M West or initiate a DFM/transfer review now to align project timing with the 2026 validation and production ramp.
Conclusion
Matrix’s move to an 88,000-square-foot Bloomingdale facility is designed to deliver measurable OEM value: more capacity through additional space and scalable cells, expanded ISO 8 cleanroom injection molding for medical devices, a structured NPI engineering lab for faster and safer launches, and a leaner layout that supports validated, traceable production.
For medical device OEMs and contract manufacturers, the phased 2026 timeline enables proactive planning for transfers, validations, and multi-program scaling—supporting a long-term, risk-managed manufacturing partnership.
TL;DR: The expansion combines capacity growth, cleanroom output, NPI/validation readiness, and lean flow—built to help regulated customers scale and transfer programs with lower risk.
FAQ
Q: What does “ISO 8 cleanroom injection molding for medical devices” mean in practical terms?
A: ISO 8 is a cleanroom classification (per ISO 14644) that limits airborne particulate levels to defined thresholds. In practice, it supports cleaner handling and processing for medical molded components and assemblies where contamination control is specified, and it helps maintain repeatability during validated production runs.
Q: When should an OEM start IQ/OQ/PQ planning for a 2026 transfer to the new Bloomingdale facility?
A: Ideally, validation planning should begin during early engineering builds—well before commercial cutover—so acceptance criteria, sampling plans, and change-control expectations are aligned. With initial operational readiness targeted for Q2 2026 and ramp through end of 2026, earlier planning increases schedule certainty and reduces rework.
Q: What kinds of parts benefit most from cleanroom plastic molding and higher-cavitation tooling?
A: Small-to-medium medical components that ship at high annual volumes—such as diagnostic consumables, drug-delivery subcomponents, and certain surgical device parts—often see the biggest benefit. Higher cavitation (e.g., 8–64 cavities depending on part size) can reduce piece price and increase output, while cleanroom processing supports contamination requirements.
Q: What should I include in an RFQ for medical device injection molding and precision tooling?
A: Provide the 2D drawing and 3D CAD, CTQs, annualized volume and ramp assumptions, resin requirements, any sterilization method, packaging requirements, and validation/documentation expectations (IQ/OQ/PQ, traceability, inspection reporting). If you have prior capability data or known failure modes, include those as well.
Q: How can customers reduce supply risk during the facility transition?
A: Common approaches include phased transfers by SKU family, bridging builds (safety stock) before equipment moves, and early agreement on what changes require revalidation. A disciplined change-control process and clear qualification timeline help ensure continuity of supply and regulatory compliance during the ramp.